Benitec Biopharma (BNTC) Price-to-Projected Revenue Ratio
The forward price-to-sales valuation reflects the cost dynamics of Benitec Biopharma Inc. (BNTC), where the 8841.90 mark serves as the current indicator. Benitec Biopharma Inc. (BNTC) utilizes RNA interference to block pathogenic genes and treat rare diseases. The production cycle relies on contract manufacturing organizations (CMO) supported by in-house R&D centers. Current management success and market capitalization depend on the outcomes of gene therapy clinical trials.
Metric breakdowns and analytics for Benitec Corp (BNTC)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Benitec Biopharma Inc.|BNTC - Long-Term Debt to Capital|Short-Term Debt to Equity Benitec Biopharma Inc.|BNTC - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Benitec Corp|BNTC - Company Long-Term Liabilities|Company Short-Term Debts Benitec Biopharma|Quick Liquidity Indicator benitec.com
- business earnings and investment ratios data:
BNTC - Final Profit|Projected Future Earnings Benitec Biopharma Inc.|BNTC - Business Payback Period|Future Price to Earnings Benitec|BNTC - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Benitec Corp|BNTC - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Benitec Biopharma|BNTC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth benitec.com|BNTC - Earnings per share growth in current year|Net earnings per share growth forecast for next year Benitec Biopharma Inc.
- sales volume and revenue information:
Summary company analysis:BNTC (Benitec Biopharma)
For Benitec Biopharma Inc. (BNTC), which is developing breakthrough ddRNAi technology for the treatment of rare diseases, the expected P/S metric serves as a tool to verify market value relative to projected revenue. Comparing market capitalization with future sales allows investors to filter out speculative noise, revealing whether the company's assets are truly overvalued or undervalued during the clinical trial stage before actual financial results are realized.
Competitors of Benitec Biopharma Inc. (BNTC)
Forward P/S Multiple TEM (Tempus AI, Inc.)|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Repligen Inc.|Avidity Biosciences (RNA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CRSP (crisprtx.com)|WGS (GeneDx) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward P/S Multiple BEAM|Forward P/S Multiple Sarepta Corp (SRPT)|Price-to-Projected Revenue Ratio Twist Bioscience TWST|Forward Price to Sales TXG|NTLA - Price-to-Projected Revenue Ratio|Stoke Therapeutics Inc (STOK) - Forward Price-to-Revenue Multiple|BLFS: Forward P/S Multiple|Wave Pharma (WVE) - Forward P/S Multiple|Forward Price-to-Revenue Multiple MAZE|SION: Forward Price to Sales|Forward P/S Multiple PRME|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX: Market Cap to Projected Revenue|REGENXBIO Inc. - Forward P/S Multiple|solidbio.com (SLDB) - Forward Price-to-Revenue Multiple|OCGN (Ocugen) - Forward Price-to-Revenue Multiple|PACB - Market Cap to Expected Sales Ratio|DSGN (Design Pharma) - Forward P/S Multiple|Price-to-Projected Revenue Ratio RCKT|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|lexeotx.com - Market Cap to Projected Revenue|Korro Bio - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio EDIT (Editas Medicine Inc)|Silence Therapeutics Inc. - Forward P/S Multiple|ProQR Therapeutics N.V. (PRQR) - Forward Price-to-Revenue Multiple|CDXS: Forward P/S Multiple|Market Cap to Projected Revenue SGMO|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|Forward P/S Multiple generationbio.com (GBIO)|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|Exicure Inc. - Price-to-Projected Revenue Ratio|Celsion Corporation - Forward P/S Multiple|Market Cap to Future Revenue Ratio Phio Pharmaceuticals|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue RNAZ|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|Price to Expected Revenue Ratio IPA|Forward P/S Multiple OMGA (Omega)|Singular Genomics Corp (OMIC) - Market Cap to Future Revenue Ratio|Regulus Therapeutics - Forward P/S Multiple|syros.com (SYRS) - Forward Price-to-Revenue Multiple|TBIO (Telesis Bio) - Forward Price-to-Revenue Multiple|TRACON Pharmaceuticals Inc. - Forward Price to Sales|UBX (Unity Bio) - Forward P/S Multiple
